GrippeCanadaV3, Main, Exploration, bibRecord, 000183

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.

Identifieur interne : 000183 ( Main/Exploration ); précédent : 000182; suivant : 000184

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.

Auteurs : Sakara Hutspardol [Canada] ; Mohammed Essa [Arabie saoudite] ; Susan Richardson [Canada] ; Tal Schechter [Canada] ; Muhammad Ali [Canada] ; Joerg Krueger [Canada] ; Hisaki Fujii [Canada] ; R Maarten Egeler [Canada] ; Adam Gassas [Canada]

Source :

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [ 1523-6536 ] ; 2015.

RBID : pubmed:26117558

Descripteurs français

KwdFr :
- Adolescent, Allogreffes, Antibioprophylaxie, Antiviraux (usage thérapeutique), Association thérapeutique, Canada (épidémiologie), Enfant, Enfant d'âge préscolaire, Environnement contrôlé, Femelle, Humains, Hémopathies (), Incidence, Infections de l'appareil respiratoire (), Infections de l'appareil respiratoire (diagnostic), Infections de l'appareil respiratoire (mortalité), Infections de l'appareil respiratoire (virologie), Insuffisance respiratoire (mortalité), Insuffisance respiratoire (étiologie), Lymphohistiocytose hémophagocytaire (), Maladies génétiques congénitales (), Maladies virales (mortalité), Maladies virales (virologie), Mâle, Neutropénie fébrile (traitement médicamenteux), Nourrisson, Nouveau-né, Pneumopathie virale (), Pneumopathie virale (mortalité), Pneumopathie virale (virologie), Risque, Résultat thérapeutique, Soutien nutritionnel, Sujet immunodéprimé, Transplantation autologue, Transplantation de cellules souches hématopoïétiques, Tumeurs (), Études de suivi, Études rétrospectives.
MESH :
- diagnostic : Infections de l'appareil respiratoire.
- mortalité : Infections de l'appareil respiratoire, Insuffisance respiratoire, Maladies virales, Pneumopathie virale.
- traitement médicamenteux : Neutropénie fébrile.
- usage thérapeutique : Antiviraux.
- virologie : Infections de l'appareil respiratoire, Maladies virales, Pneumopathie virale.
- épidémiologie : Canada.
- étiologie : Insuffisance respiratoire.
- Adolescent, Allogreffes, Antibioprophylaxie, Association thérapeutique, Enfant, Enfant d'âge préscolaire, Environnement contrôlé, Femelle, Humains, Hémopathies, Incidence, Infections de l'appareil respiratoire, Lymphohistiocytose hémophagocytaire, Maladies génétiques congénitales, Mâle, Nourrisson, Nouveau-né, Pneumopathie virale, Risque, Résultat thérapeutique, Soutien nutritionnel, Sujet immunodéprimé, Transplantation autologue, Transplantation de cellules souches hématopoïétiques, Tumeurs, Études de suivi, Études rétrospectives.
Wicri :
- geographic : Canada.

English descriptors

KwdEn :
- Adolescent, Allografts, Antibiotic Prophylaxis, Antiviral Agents (therapeutic use), Canada (epidemiology), Child, Child, Preschool, Combined Modality Therapy, Environment, Controlled, Febrile Neutropenia (drug therapy), Female, Follow-Up Studies, Genetic Diseases, Inborn (therapy), Hematologic Diseases (therapy), Hematopoietic Stem Cell Transplantation, Humans, Immunocompromised Host, Incidence, Infant, Infant, Newborn, Lymphohistiocytosis, Hemophagocytic (therapy), Male, Neoplasms (therapy), Nutritional Support, Pneumonia, Viral (mortality), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Respiratory Insufficiency (etiology), Respiratory Insufficiency (mortality), Respiratory Tract Infections (diagnosis), Respiratory Tract Infections (mortality), Respiratory Tract Infections (therapy), Respiratory Tract Infections (virology), Retrospective Studies, Risk, Transplantation, Autologous, Treatment Outcome, Virus Diseases (mortality), Virus Diseases (virology).
MESH :
- chemical , therapeutic use : Antiviral Agents.
- geographic , epidemiology : Canada.
- diagnosis : Respiratory Tract Infections.
- drug therapy : Febrile Neutropenia.
- etiology : Respiratory Insufficiency.
- mortality : Pneumonia, Viral, Respiratory Insufficiency, Respiratory Tract Infections, Virus Diseases.
- therapy : Genetic Diseases, Inborn, Hematologic Diseases, Lymphohistiocytosis, Hemophagocytic, Neoplasms, Pneumonia, Viral, Respiratory Tract Infections.
- virology : Pneumonia, Viral, Respiratory Tract Infections, Virus Diseases.
- Adolescent, Allografts, Antibiotic Prophylaxis, Child, Child, Preschool, Combined Modality Therapy, Environment, Controlled, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Immunocompromised Host, Incidence, Infant, Infant, Newborn, Male, Nutritional Support, Retrospective Studies, Risk, Transplantation, Autologous, Treatment Outcome.

Abstract

Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell transplantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When screening for causes of death in the first year after HSCT in the 844 patients, we found that RVI as a cause of death was only evident in the first 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI within the first 100 days after HSCT (allogeneic = 32, autologous = 22). Upper and lower respiratory tract infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainfluenza (35%), respiratory syncytial virus (28%), influenza (22%), adenovirus (7%), human metapneumovirus (4%), coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic = 4, autologous = 1). All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P = .03). Given the significant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT, whenever possible, may help prevent RVI and improve outcomes.

DOI: 10.1016/j.bbmt.2015.06.015
PubMed: 26117558

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000200
to stream Main, to step Curation: 000200

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.</title>
<author><name sortKey="Hutspardol, Sakara" sort="Hutspardol, Sakara" uniqKey="Hutspardol S" first="Sakara" last="Hutspardol">Sakara Hutspardol</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada. Electronic address: sakara4695@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Essa, Mohammed" sort="Essa, Mohammed" uniqKey="Essa M" first="Mohammed" last="Essa">Mohammed Essa</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Haematology/Oncology/SCT, King Saud bin Abdulaziz University for Health Sciences, King Abdullah Specialized Children's Hospital Riyadh, Saudi Arabia.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Division of Haematology/Oncology/SCT, King Saud bin Abdulaziz University for Health Sciences, King Abdullah Specialized Children's Hospital Riyadh</wicri:regionArea>
<wicri:noRegion>King Abdullah Specialized Children's Hospital Riyadh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Richardson, Susan" sort="Richardson, Susan" uniqKey="Richardson S" first="Susan" last="Richardson">Susan Richardson</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Microbiology, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Microbiology, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schechter, Tal" sort="Schechter, Tal" uniqKey="Schechter T" first="Tal" last="Schechter">Tal Schechter</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ali, Muhammad" sort="Ali, Muhammad" uniqKey="Ali M" first="Muhammad" last="Ali">Muhammad Ali</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krueger, Joerg" sort="Krueger, Joerg" uniqKey="Krueger J" first="Joerg" last="Krueger">Joerg Krueger</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fujii, Hisaki" sort="Fujii, Hisaki" uniqKey="Fujii H" first="Hisaki" last="Fujii">Hisaki Fujii</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Egeler, R Maarten" sort="Egeler, R Maarten" uniqKey="Egeler R" first="R Maarten" last="Egeler">R Maarten Egeler</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gassas, Adam" sort="Gassas, Adam" uniqKey="Gassas A" first="Adam" last="Gassas">Adam Gassas</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26117558</idno>
<idno type="pmid">26117558</idno>
<idno type="doi">10.1016/j.bbmt.2015.06.015</idno>
<idno type="wicri:Area/Main/Corpus">000200</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000200</idno>
<idno type="wicri:Area/Main/Curation">000200</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000200</idno>
<idno type="wicri:Area/Main/Exploration">000200</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.</title>
<author><name sortKey="Hutspardol, Sakara" sort="Hutspardol, Sakara" uniqKey="Hutspardol S" first="Sakara" last="Hutspardol">Sakara Hutspardol</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada. Electronic address: sakara4695@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Essa, Mohammed" sort="Essa, Mohammed" uniqKey="Essa M" first="Mohammed" last="Essa">Mohammed Essa</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Haematology/Oncology/SCT, King Saud bin Abdulaziz University for Health Sciences, King Abdullah Specialized Children's Hospital Riyadh, Saudi Arabia.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Division of Haematology/Oncology/SCT, King Saud bin Abdulaziz University for Health Sciences, King Abdullah Specialized Children's Hospital Riyadh</wicri:regionArea>
<wicri:noRegion>King Abdullah Specialized Children's Hospital Riyadh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Richardson, Susan" sort="Richardson, Susan" uniqKey="Richardson S" first="Susan" last="Richardson">Susan Richardson</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Microbiology, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Microbiology, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schechter, Tal" sort="Schechter, Tal" uniqKey="Schechter T" first="Tal" last="Schechter">Tal Schechter</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ali, Muhammad" sort="Ali, Muhammad" uniqKey="Ali M" first="Muhammad" last="Ali">Muhammad Ali</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krueger, Joerg" sort="Krueger, Joerg" uniqKey="Krueger J" first="Joerg" last="Krueger">Joerg Krueger</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fujii, Hisaki" sort="Fujii, Hisaki" uniqKey="Fujii H" first="Hisaki" last="Fujii">Hisaki Fujii</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Egeler, R Maarten" sort="Egeler, R Maarten" uniqKey="Egeler R" first="R Maarten" last="Egeler">R Maarten Egeler</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gassas, Adam" sort="Gassas, Adam" uniqKey="Gassas A" first="Adam" last="Gassas">Adam Gassas</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</title>
<idno type="eISSN">1523-6536</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Allografts</term>
<term>Antibiotic Prophylaxis</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Canada (epidemiology)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Combined Modality Therapy</term>
<term>Environment, Controlled</term>
<term>Febrile Neutropenia (drug therapy)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Genetic Diseases, Inborn (therapy)</term>
<term>Hematologic Diseases (therapy)</term>
<term>Hematopoietic Stem Cell Transplantation</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Incidence</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Lymphohistiocytosis, Hemophagocytic (therapy)</term>
<term>Male</term>
<term>Neoplasms (therapy)</term>
<term>Nutritional Support</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Respiratory Insufficiency (etiology)</term>
<term>Respiratory Insufficiency (mortality)</term>
<term>Respiratory Tract Infections (diagnosis)</term>
<term>Respiratory Tract Infections (mortality)</term>
<term>Respiratory Tract Infections (therapy)</term>
<term>Respiratory Tract Infections (virology)</term>
<term>Retrospective Studies</term>
<term>Risk</term>
<term>Transplantation, Autologous</term>
<term>Treatment Outcome</term>
<term>Virus Diseases (mortality)</term>
<term>Virus Diseases (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Allogreffes</term>
<term>Antibioprophylaxie</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association thérapeutique</term>
<term>Canada (épidémiologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Environnement contrôlé</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémopathies ()</term>
<term>Incidence</term>
<term>Infections de l'appareil respiratoire ()</term>
<term>Infections de l'appareil respiratoire (diagnostic)</term>
<term>Infections de l'appareil respiratoire (mortalité)</term>
<term>Infections de l'appareil respiratoire (virologie)</term>
<term>Insuffisance respiratoire (mortalité)</term>
<term>Insuffisance respiratoire (étiologie)</term>
<term>Lymphohistiocytose hémophagocytaire ()</term>
<term>Maladies génétiques congénitales ()</term>
<term>Maladies virales (mortalité)</term>
<term>Maladies virales (virologie)</term>
<term>Mâle</term>
<term>Neutropénie fébrile (traitement médicamenteux)</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Pneumopathie virale ()</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Risque</term>
<term>Résultat thérapeutique</term>
<term>Soutien nutritionnel</term>
<term>Sujet immunodéprimé</term>
<term>Transplantation autologue</term>
<term>Transplantation de cellules souches hématopoïétiques</term>
<term>Tumeurs ()</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Febrile Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Pneumonia, Viral</term>
<term>Respiratory Insufficiency</term>
<term>Respiratory Tract Infections</term>
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
<term>Insuffisance respiratoire</term>
<term>Maladies virales</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Genetic Diseases, Inborn</term>
<term>Hematologic Diseases</term>
<term>Lymphohistiocytosis, Hemophagocytic</term>
<term>Neoplasms</term>
<term>Pneumonia, Viral</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Neutropénie fébrile</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
<term>Maladies virales</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pneumonia, Viral</term>
<term>Respiratory Tract Infections</term>
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Insuffisance respiratoire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Allografts</term>
<term>Antibiotic Prophylaxis</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Combined Modality Therapy</term>
<term>Environment, Controlled</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Hematopoietic Stem Cell Transplantation</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Incidence</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Male</term>
<term>Nutritional Support</term>
<term>Retrospective Studies</term>
<term>Risk</term>
<term>Transplantation, Autologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Allogreffes</term>
<term>Antibioprophylaxie</term>
<term>Association thérapeutique</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Environnement contrôlé</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémopathies</term>
<term>Incidence</term>
<term>Infections de l'appareil respiratoire</term>
<term>Lymphohistiocytose hémophagocytaire</term>
<term>Maladies génétiques congénitales</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Pneumopathie virale</term>
<term>Risque</term>
<term>Résultat thérapeutique</term>
<term>Soutien nutritionnel</term>
<term>Sujet immunodéprimé</term>
<term>Transplantation autologue</term>
<term>Transplantation de cellules souches hématopoïétiques</term>
<term>Tumeurs</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell transplantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When screening for causes of death in the first year after HSCT in the 844 patients, we found that RVI as a cause of death was only evident in the first 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI within the first 100 days after HSCT (allogeneic = 32, autologous = 22). Upper and lower respiratory tract infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainfluenza (35%), respiratory syncytial virus (28%), influenza (22%), adenovirus (7%), human metapneumovirus (4%), coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic = 4, autologous = 1). All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P = .03). Given the significant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT, whenever possible, may help prevent RVI and improve outcomes.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26117558</PMID>
<DateCompleted><Year>2016</Year>
<Month>06</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>10</Issue>
<PubDate><Year>2015</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title>
<ISOAbbreviation>Biol. Blood Marrow Transplant.</ISOAbbreviation>
</Journal>
<ArticleTitle>Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.</ArticleTitle>
<Pagination><MedlinePgn>1802-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2015.06.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1083-8791(15)00417-6</ELocationID>
<Abstract><AbstractText>Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell transplantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When screening for causes of death in the first year after HSCT in the 844 patients, we found that RVI as a cause of death was only evident in the first 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI within the first 100 days after HSCT (allogeneic = 32, autologous = 22). Upper and lower respiratory tract infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainfluenza (35%), respiratory syncytial virus (28%), influenza (22%), adenovirus (7%), human metapneumovirus (4%), coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic = 4, autologous = 1). All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P = .03). Given the significant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT, whenever possible, may help prevent RVI and improve outcomes.</AbstractText>
<CopyrightInformation>Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hutspardol</LastName>
<ForeName>Sakara</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada. Electronic address: sakara4695@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Essa</LastName>
<ForeName>Mohammed</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/SCT, King Saud bin Abdulaziz University for Health Sciences, King Abdullah Specialized Children's Hospital Riyadh, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Richardson</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Microbiology, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schechter</LastName>
<ForeName>Tal</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>Muhammad</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Krueger</LastName>
<ForeName>Joerg</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fujii</LastName>
<ForeName>Hisaki</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Egeler</LastName>
<ForeName>R Maarten</ForeName>
<Initials>RM</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gassas</LastName>
<ForeName>Adam</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Haematology/Oncology/BMT, the Hospital for Sick Children, University of Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>06</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biol Blood Marrow Transplant</MedlineTA>
<NlmUniqueID>9600628</NlmUniqueID>
<ISSNLinking>1083-8791</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004780" MajorTopicYN="N">Environment, Controlled</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064147" MajorTopicYN="N">Febrile Neutropenia</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030342" MajorTopicYN="N">Genetic Diseases, Inborn</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006402" MajorTopicYN="N">Hematologic Diseases</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051359" MajorTopicYN="N">Lymphohistiocytosis, Hemophagocytic</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword>
<Keyword MajorTopicYN="N">Hematopoietic stem cell transplantation</Keyword>
<Keyword MajorTopicYN="N">Mortality</Keyword>
<Keyword MajorTopicYN="N">Respiratory virus infection</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>04</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>06</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>6</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>6</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>6</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26117558</ArticleId>
<ArticleId IdType="pii">S1083-8791(15)00417-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbmt.2015.06.015</ArticleId>
<ArticleId IdType="pmc">PMC7110880</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2014 Jan;52(1):350-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24131690</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2001 Sep;28(5):479-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11593321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2003 May;9(5):341-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12766884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Infect Dis. 2015 Apr;17(2):242-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25648539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2004 Nov 1;39(9):1300-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15494906</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Natl Cancer Inst. 2000 Feb 2;92(3):205-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10655437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Feb 1;46(3):402-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18181739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2010 Dec 16;116(25):5476-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20837781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2005 Oct;11(10):781-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16182179</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2011 Mar 10;117(10):2755-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21139081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Jan 23;32(5):585-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24333120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Hematol. 2014 Apr;93(4):669-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24097084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Respir Crit Care Med. 2007 Apr;28(2):222-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17458776</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2003 Feb;31(4):309-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12621469</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2011 Mar;17(3):434-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20950701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2014 Feb;20(2):250-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24269896</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2005 Nov;36(10):897-900</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16170332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intern Med. 2014;53(5):499-503</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24583443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2007 Oct 15;45(8):1019-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17879919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Infect Dis. 2009 Aug;11(4):373-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19392729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1992 Apr 2;326(14):921-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1311800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2001 Oct 1;33(7):962-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11528566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transpl Infect Dis. 2013 Oct;15(5):487-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23890293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2006 Aug 1;43(3):331-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16804849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2010 Sep;16(9):1265-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20304082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2008 Nov;42(10):637-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18724396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 1996 Nov;23(5):1033-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8922798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1998 Nov;36(11):3149-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9774555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transplant. 2012 Sep-Oct;26(5):736-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22385011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Haematol. 2004 Nov;127(3):322-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15491293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2013 Aug 15;122(7):1316-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23744585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Medicine (Baltimore). 2006 Sep;85(5):278-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16974212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Hematol Oncol. 2005 Jun;22(4):271-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16020113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Aug 15;194(4):474-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16845630</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2013 Jun;48(6):803-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23178547</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Haematologica. 2007 Sep;92(9):1254-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17666361</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):128-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19147091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2002 Sep 1;100(5):1619-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12176880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2010 Mar 11;115(10):2088-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20042728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2001 Aug 1;98(3):573-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11468152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2001 Jan;39(1):196-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11136770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2002 Feb;29(4):321-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11896429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2006 May 27;81(10):1398-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16732176</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2002 Jan 15;34(2):177-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11740705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2010 Apr;24(4):706-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20147979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Infect Dis. 2002 Aug;15(4):355-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12130931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bone Marrow Transplant. 2004 May;33(9):931-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 1993 Sep;12(9):699-701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8243487</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Arabie saoudite</li>
<li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Hutspardol, Sakara" sort="Hutspardol, Sakara" uniqKey="Hutspardol S" first="Sakara" last="Hutspardol">Sakara Hutspardol</name>
</region>
<name sortKey="Ali, Muhammad" sort="Ali, Muhammad" uniqKey="Ali M" first="Muhammad" last="Ali">Muhammad Ali</name>
<name sortKey="Egeler, R Maarten" sort="Egeler, R Maarten" uniqKey="Egeler R" first="R Maarten" last="Egeler">R Maarten Egeler</name>
<name sortKey="Fujii, Hisaki" sort="Fujii, Hisaki" uniqKey="Fujii H" first="Hisaki" last="Fujii">Hisaki Fujii</name>
<name sortKey="Gassas, Adam" sort="Gassas, Adam" uniqKey="Gassas A" first="Adam" last="Gassas">Adam Gassas</name>
<name sortKey="Krueger, Joerg" sort="Krueger, Joerg" uniqKey="Krueger J" first="Joerg" last="Krueger">Joerg Krueger</name>
<name sortKey="Richardson, Susan" sort="Richardson, Susan" uniqKey="Richardson S" first="Susan" last="Richardson">Susan Richardson</name>
<name sortKey="Schechter, Tal" sort="Schechter, Tal" uniqKey="Schechter T" first="Tal" last="Schechter">Tal Schechter</name>
</country>
<country name="Arabie saoudite"><noRegion><name sortKey="Essa, Mohammed" sort="Essa, Mohammed" uniqKey="Essa M" first="Mohammed" last="Essa">Mohammed Essa</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000183 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000183 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26117558
   |texte=   Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26117558" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.

Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki